Urothelial carcinoma with squamous differentiation: Response to chemotherapy and radiation

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 10, 2015, Pages 434-436

  Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Radiation therapy; Squamous differentiation; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; HISTOLOGY; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; CARCINOMA, TRANSITIONAL CELL; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; HUMANS; RADIOTHERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84942191632     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.06.019     Document Type: Review

References (13)

1. Martin J.E., Jenkins B.J., Zuk R.J., et al. Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol 1989, 42:250.
2. Lopez-Beltran A., Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006, 37:1371.
3. Logothetis C.J., Samuels M.L., Ogden S., et al. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 1985, 134:460.
4. Logothetis C.J., Dexeus F.H., Chong C., et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989, 141:33.
5. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997, 15:2564.
6. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002, 95:751.
7. Kastritis E., Dimopoulos M.A., Antoniou N., et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res 2006, 26:3865.
8. Logothetis C.J., Johnson D.E., Chong C., et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988, 6:1590.
9. Scosyrev E., Ely B.W., Messing E.M., et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 2011, 108:693.
10. Jenkins B.J., Martin J.E., Baithun S.I., et al. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol 1990, 65:345.
11. Vale J.A., A'Hern R.P., Liu K., et al. Predicting the outcome of radical radiotherapy for invasive bladder cancer. Eur Urol 1993, 24:48.
12. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012, 366:1477.
13. Choi W., Czerniak B., Ochoa A., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2014, 11:400.